The efficacy and safety of low-dose rituximab in treatment of primary Sj(..o)gren's syndrome with thrombocytopenia
10.3760/cma.j.issn.0578-1426.2012.01.010
- VernacularTitle:小剂量利妥昔单抗治疗原发性干燥综合征继发血小板减少四例疗效观察
- Author:
Li ZHOU
;
Xiafei XIN
;
Huaxiang WU
- Publication Type:Journal Article
- Keywords:
Rituximab;
Sj(..o)gren's syndrome;
Thrombocytopenia
- From:
Chinese Journal of Internal Medicine
2012;51(1):37-41
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of low-dose rituximab (RTX) for patients in primary Sj(..o)gren's syndrome (pSS) with thrombocytopenia.Methods Four pSS patients,2 with refractory thrombocytopenia and 2 with glucocorticoid-dependent thrombocytopenia,were treated with rituximab at 100 mg,intravenous,weekly for a total of two cycles,together with prednisone 1-2 mg · kg-1 ·d-1,and the counts of platelets and B-cells were evaluated.Results Efficacy of treatment was observed in all patients.The counts of platelets,at (3-39) x 109/L baseline,incleased in 1-2 weeks,and went up to ( 107-241 ) × 109/L in 3-8 weeks.Sustained remission had been achieved for 27-52 weeks.The doses of prednisone were tappered to 3.75-7.50 mg/day in 12 weeks.One patient who relapsed at the 27th week (platelet count 47 x 109/L),was retreated with 100 mg of RTX and still had good efficacy.The counts of B-cells reduced to (0.007-0.010) × 109/L,but they did not achieved the depletion.There were no severe adverse events during RTX therapy.Conclusions Our study has shown good efficacy and tolerability of lowdose RTX for pSS with thrombocytopenia.Low-dose RTX allows for reduction in corticosteroid doses and B-cells,while large-scale randomized double-blind controlled trials are needed to confirm the results.
